APRE News

Even biotechs aren't immune to the newly-challenging IPO market. Six companies were scheduled to price IPOs this past week, but only four entered the public market; one biotech postponed while another - the largest - withdrew its IPO plans. All four priced at or below the midpoint. There was also a spike in initial filings, with eight companies and one SPAC entering the IPO pipeline...read more

Aprea Therapeutics, a Phase 3 biotech developing targeted therapies for cancer, raised $85 million by offering 5.7 million shares at $15, the midpoint of the $14 to $16 range. The company upsized its offering by 0.67 million shares ($10 million). Aprea Therapeutics plans to list on the Nasdaq under the symbol APRE. J.P. Morgan, Morgan Stanley and RBC Capital Markets acted as...read more

After a wave of biotech launches last week, one more filed terms this week. Seven biotechs are currently on the Renaissance IPO calendar, four of which are targeting billion-dollar valuations. Five are set to price tonight. Swiss biotech ADC Therapeutics (ADCT) plans to raise $200 million by offering 8.2 million shares at a range of $23 to $26 to command a $1...read more

Six IPOs plan to raise $596 million in the week ahead, with two biotechs targeting billion-dollar-plus valuations. Swiss biotech ADC Therapeutics (ADCT) plans to raise $200 million at a $1.8 billion valuation. Insiders have indicated on $115 million of the IPO. The company is developing antibody drug conjugates, and its pipeline consists of seven candidates...read more